论文部分内容阅读
目的:比较长春西汀和舒血宁治疗椎基底动脉供血不足的最小成本。方法:选取2009年6月～2010年6月我院神经内科82例椎基底动脉供血不足的住院患者,将采用长春西汀注射液治疗者作为A组,给予舒血宁注射液治疗者作为B组,进行最小成本分析。结果:A组和B组的治疗总有效率分另别为95.23%和92.50%,差异无统计学意义(P>0.05);治疗药物成本分别为1156.4元和834.4元。结论:根据药物经济学评价,,以加用舒血宁注射液的治疗方案成本较低,值得选择应用。
OBJECTIVE: To compare the minimal cost of vinpocetine and Shuxuening in treating vertebrobasilar insufficiency. Methods: From June 2009 to June 2010, 82 patients with vertebrobasilar insufficiency in our department of neurology were enrolled. Patients in Group B were treated with Vinpocetine Injection and Group B with Shuxuening Injection. Group for minimum cost analysis. Results: The total effective rate was 95.23% and 92.50% in group A and group B, respectively, with no significant difference (P> 0.05). The cost of treatment was 1156.4 yuan and 834.4 yuan respectively. Conclusion: According to the evaluation of pharmacoeconomics, the cost of treatment with Shuxuening Injection is lower and it is worth to choose and apply.